BCAB - NASDAQ

BioAtla, Inc.

BioAtla, Inc.

BCABยทNASDAQ

$0.89

+8.2%
HealthcareBiotechnology

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$52.38M
EPS-1.4400
P/E Ratio-0.62
Earnings Date03/26/2026
BioAtla, Inc.

BioAtla, Inc. Fair Value Envelope

BCAB ยท NASDAQ

Our analysis suggests that BCAB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $0.8909, this represents a potential HIDDEN relative to our calculated worth for BioAtla, Inc..

HIDDEN
Intrinsic Value
Current Price: $0.8909

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$2.4B
+ Cash & Equivalents$49.0M
Firm Value-$2.4B
- Debt$836.0K
Equity Value-$2.4B
/ Shares Outstanding58,792,088B
DCF Value-$40
OVERVALUED BY 4595%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$94.2M
-$123.3M
-$161.4M
-$211.2M
-$276.5M
-$362.0M
-$473.9M
-$620.3M
-$812.0M
-$1.1B
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$94.2M
-$123.3M
-$161.4M
-$211.2M
-$276.5M
-$362.0M
-$473.9M
-$620.3M
-$812.0M
-$1.1B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$87.2M
-$105.7M
-$128.1M
-$155.3M
-$188.2M
-$228.1M
-$276.5M
-$335.1M
-$406.2M
-$492.4M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your BCAB research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.